Hematology

Latest News

After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

June 26th 2025

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Multi-hit TP53 mutations are a significant negative prognostic factor for patients with both MPN and AML, the new study found. | Image credit: MdBabul - stock.adobe.com
Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

June 20th 2025

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

conceptual image of therapy | Image Credit: ArtemisDiana-stock.adobe.com
June 13th 2024

Induction Treatment Based on Pharmacogenomics May Address Racial Disparities in AML

AJMC Contributor
Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single-nucleotide variant score could better treatment for these young patients, particularly those who are Black.
hemophilia | Image Credit: jarun011-stock.adobe.com
June 13th 2024

Emicizumab Has Strong Safety, Efficacy Record in Real-World Usage

Jared Kaltwasser
The most common treatment-related adverse events were injection site reactions, the study found.
multiple myeloma diagnosis | Image Credit: shidlovski-stock.adobe.com
June 13th 2024

MRD2STOP: Promise in Halting Myeloma Maintenance Therapy

Maggie L. Shaw
One patient died during this study, which used PET/CT, flow cytometry, and next-generation sequencing to define measurable residual disease negativity.
The Future of Acquired TTP
August 31st 2021

The Future of Acquired TTP

X. Long Zheng, MD, PhD
X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment.
Treatment Considerations for Caplacizumab
August 26th 2021

Treatment Considerations for Caplacizumab

X. Long Zheng, MD, PhD
X. Long Zheng, MD, PhD, explains when physicians should administer caplacizumab after suspecting a diagnosis of acquired TTP, and discusses the risk of relapse or refractory disease.
Using Caplacizumab to Treat Acquired TTP
August 24th 2021

Using Caplacizumab to Treat Acquired TTP

X. Long Zheng, MD, PhD
An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial.
Treatment Options for Acquired TTP
August 19th 2021

Treatment Options for Acquired TTP

X. Long Zheng, MD, PhD
X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider.
Diagnostic Approach to Acquired TTP
August 17th 2021

Diagnostic Approach to Acquired TTP

X. Long Zheng, MD, PhD
A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing.
Overview of Acquired Thrombotic Thrombocytopenic Purpura
August 13th 2021

Overview of Acquired Thrombotic Thrombocytopenic Purpura

X. Long Zheng, MD, PhD
X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation.
ACIP Votes to Lift Pause on J&J COVID-19 Vaccine
April 23rd 2021

ACIP Votes to Lift Pause on J&J COVID-19 Vaccine

Gianna Melillo
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
vials with blood samples
April 15th 2021

Carfilzomib, Bortezomib Combo Shows Potential for Reducing Tumor Growth in Melanoma Cells

Jaime Rosenberg
The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.
CDC, FDA Call for Pause of J&J COVID-19 Vaccine After Safety Concerns Around Clotting
April 13th 2021

CDC, FDA Call for Pause of J&J COVID-19 Vaccine After Safety Concerns Around Clotting

Laura Joszt, MA
After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.
Older woman with cane
April 9th 2021

Bortezomib Appears to Increase Fall Risk in Elderly Patients With MM, Study Suggests

Jared Kaltwasser
Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.
FDA Approves Isatuximab, Carfilzomib, Dexamethasone Combination for RRMM
April 3rd 2021

FDA Approves Isatuximab, Carfilzomib, Dexamethasone Combination for RRMM

AJMC Staff
Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.
The Impact of Sickle Cell Disease Severity on HRQOL and Economic Outcomes
April 1st 2021

The Impact of Sickle Cell Disease Severity on HRQOL and Economic Outcomes

Laura Joszt, MA
Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.
NCCN
March 24th 2021

Many Options, Many Updates to NCCN Guidelines in Multiple Myeloma

Mary Caffrey
Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.
Drug development
March 16th 2021

Lenacapavir Against HIV Demonstrates Ongoing Potential

Maggie L. Shaw
The safety and effectiveness of the long-acting agent is backed by data from trials of the drug among treatment-experienced individuals living with HIV-1 whose viral load is on the rise due to other regimens failing. Investigation continues among these patients, as well as treatment-naive patients.
Report Describes Case of Improved Outcome in MM With Personalized Medicine
March 6th 2021

Report Describes Case of Improved Outcome in MM With Personalized Medicine

Larry Hanover
Researchers describe the case of an older patient who underwent myeloma drug sensitivity testing as part of an effort to identify the therapies most likely to produce a response in this difficult-to-treat population.
Marrow Lymphocyte Patterns After ASCT May Have Prognostic Value in MM
March 5th 2021

Marrow Lymphocyte Patterns After ASCT May Have Prognostic Value in MM

Jaime Rosenberg
Patients with multiple myeloma (MM) often relapse over time despite initially achieving a complete response without minimal residual disease following induction treatment, leaving questions about changes in the immune system and the prognosis of the disease.
Trial of Anti-BCMA ide-cel for RRMM Leads to Undetectable Disease in 33% of Patients
February 27th 2021

Trial of Anti-BCMA ide-cel for RRMM Leads to Undetectable Disease in 33% of Patients

Allison Inserro
More than 2 years after treatment, some of the patients with relapsed/refractory multiple myeloma have yet to see a relapse. An FDA decision on the therapy is expected within a month.
FDA Clears Peptide-Drug Conjugate for RRMM
February 27th 2021

FDA Clears Peptide-Drug Conjugate for RRMM

AJMC Staff
The peptide-drug conjugate rapidly delivers an alkylating payload into tumor cells.
Combination Treatment Maintains Quality of Life in Relapsed/Refractory MM
February 20th 2021

Combination Treatment Maintains Quality of Life in Relapsed/Refractory MM

Larry Hanover
Health-related quality of life was maintained when treating relapsed/refractory multiple myeloma (RRMM) with daratumumab in combination with bortezomib and dexamethasone.
Blood Cells
February 16th 2021

Sustained MRD Negativity Predictive of Long-term Outcomes in RRMM

Rose McNulty
Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.
Blood
February 12th 2021

Carfilzomib Improves Renal Response Compared With Bortezomib in RRMM

Rose McNulty
Carfilzomib-dexamethasone improved renal overall and complete response in patients with relapsed or refractory multiple myeloma (RRMM) compared with a regimen of bortezomib-dexamethasone in a real-world study.
Robert K. Massie, Jr, PhD, MA, Society for Progress
February 10th 2021

Dr Robert Massie: Patient Needs Matter for Quality of Life to Not Suffer

Whereas patient care was often bogged down in bureaucracy when he was younger, Robert K. Massie Jr, PhD, MA, of the Society for Progress, notes that hospitals and caregivers are increasingly paying attention to what makes sense for patient care.
Email being sent
February 10th 2021

What We’re Reading: EUA for Lilly’s Combination Treatment; COVID-19 Billing Waivers; Convalescent Plasma Indication Updated

AJMC Staff
The FDA issues an emergency use authorization (EUA) for Eli Lilly’s coronavirus disease 2019 (COVID-19) treatment; insurance waivers for COVID-19–related costs are starting to expire; new data update convalescent plasma’s indication.
All of the panelists for this series
February 10th 2021

The Future of R/R Multiple Myeloma Management

Experts in the management of multiple myeloma consider promising developments for the future of relapsed/refractory treatment, with special consideration to bispecific antibodies and CAR (chimeric antigen receptor) T-cell therapy.
Socioeconomics
February 6th 2021

Socioeconomic Status May Determine Patient Survival From Multiple Myeloma

Larry Hanover
Patients’ socioeconomic status is a significant factor in predicting survival rates for multiple myeloma, according to a new study.
All of the panelists for this series
February 3rd 2021

The Role of Venetoclax in R/R Multiple Myeloma

Key opinion leaders consider the role of venetoclax in managing patients with relapsed/refractory multiple myeloma.
All of the panelists for this series
February 3rd 2021

Implications of the IKEMA Interim Analysis

Expert physicians consider the practical implications of the IKEMA interim analysis of isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
<1
...
34567891011
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo